Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
28 hedge funds and large institutions have $2.78M invested in Baudax Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 8 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
8% more funds holding
Funds holding: 26 → 28 (+2)
33% less capital invested
Capital invested by funds: $4.12M → $2.78M (-$1.34M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.09M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$311K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$54.5K |
| 4 |
Renaissance Technologies
New York
|
+$48.9K |
| 5 |
VF
Virtu Financial
New York
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$113K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$90K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.1K |
| 4 |
MML Investors Services
Springfield,
Massachusetts
|
-$32K |
| 5 |
D.E. Shaw & Co
New York
|
-$18K |
BXRX Hedge Fund Activity: Q4 2021 in Review
28 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q4 2021, worth a combined $2.78M — down 33% from $4.12M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BXRX positions and 8 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.09M. The largest seller was Millennium Management, cutting an estimated $113K.
- 28 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q4 2021, up from 26 in Q3 2021.
- Funds reported $2.78M of Baudax Bio, Inc. Common Stock stock for Q4 2021, down 33% quarter-over-quarter.
- 10 funds opened new Baudax Bio, Inc. Common Stock positions in Q4 2021 and 8 closed out, a net change of +2 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q4 2021 was Armistice Capital, an estimated $2.09M added.
- The largest Baudax Bio, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $113K sold.
Based on aggregated 13F filings for Q4 2021.